Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease.

ABSTRACT: Inflammatory bowel disease, including ulcerative colitis and Crohn's disease, are chronic inflammatory disorders of the gastrointestinal tract which are characterised, in part, by an imbalance in the production of several pro- and anti-inflammatory cytokines. Although various agents are effective for inducing and maintaining remission, approximately 20% of patients are treatment-refractory and require surgery. Parenterally administered monoclonal antibody-based biologics are associated with adverse effects resulting in treatment discontinuation and/or immunogenicity, leading to loss of response to therapy. Approximately 50% of patients who initially respond to treatment with tumour necrosis factor antagonists lose response to therapy within the 1st year of treatment. Incidence of immunogen

SUBMITTER: Lefevre PLC 

PROVIDER: S-EPMC7395308 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature